US Patent

US9119848 — Morphinan derivatives for the treatment of drug overdose

Composition of Matter · Assigned to Alkermes Pharma Ireland Ltd · Expires 2031-08-30 · 5y remaining

Vulnerability score 10/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects morphinan derivatives with sustained effectiveness in treating drug toxicity and overdose.

USPTO Abstract

The instant application relates to morphinan derivatives of Formula I with sustained effectiveness in treating drug toxicity and overdose:

Drugs covered by this patent

Patent Metadata

Patent number
US9119848
Jurisdiction
US
Classification
Composition of Matter
Expires
2031-08-30
Drug substance claim
Yes
Drug product claim
No
Assignee
Alkermes Pharma Ireland Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.